Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus ± Telitacicept in PLA2R-Associated Membranous Nephropathy
ChiCTR2500112773Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Nov 2025
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in membranous glomerulonephritis (MGN) comparing Tacrolimus + Telitacicept with Tacrolimus (2 arms). Primary endpoint: Complete remission rate at week 24. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
tacrolimustelitacicept
03
Conditions
membranous glomerulonephritis (MGN)
Beyond the preview
Go deeper on ChiCTR2500112773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112773.